The report notes a 1.5% YoY revenue decline and 24% YoY EBITDA decline in Q2FY27 due to lower lenalidomide sales, but states the company remains confident of medium-term growth from semaglutide relaunch, biosimilars and CDMO expansion, maintaining a Buy rating with FY27/FY28 estimates revised down for FY27 and mixed for FY28.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
All houses
HDFC Securities
Motilal Oswal
Tata Asset Management
Mirae Asset Sharekhan
India IPO
Jainam
GEPL Capital
Way2Wealth
SBICAP Securities
Angel One
Axis Securities
ICICI Direct Research Retail
Religare
Arete Securities
Formerly known as Way2Wealth
ICICI Direct
Way2Wealth Securities
ICICI Securities
quant Mutual Fund
Kotak Securities
JM Financial
ICICI Securities – Retail
Global Markets by Vested
Ventura Securities
Prabhudas Lilladher
Industrial Asphalts
ITC Hotels
Exterminators PLC
Emkay Global
Private Client Group Research summarized from KIE research report
Kahawatte Plantations PLC
Elara Securities
1 note from Formerly known as Way2Wealth · 09 Nov 2026, 00:00 to 10 Nov 2026, 00:00 IST